Akanda

Akanda Stock-Based Compensation

The Stock-Based Compensation (SBC) of Akanda (AKAN) as of Oct 26, 2026 is 1.25 M USD. In the previous year, Stock-Based Compensation (SBC) was 559,225.00 USD — a change of 123.52% (higher).

Stock-Based Compensation

1.25 MUSD

YoY

123.52%

Last updated:

Stock-Based Compensation (SBC) of Akanda is 2023 1.25 M USD. Stock-Based Compensation (SBC) of Akanda was 2022 559,225.00 USD. It decreases by 123.52% higher compared to the previous year.

The Akanda Stock-Based Compensation history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Stock-Based Compensation
Date
Stock-Based Compensation
Jan 1, 2021
0.00 USD
Jan 1, 2022
559,225.00 USD
Jan 1, 2023
1.25 M USD
The Akanda Stock-Based Compensation history
YEARStock-Based CompensationYoY
1.25 MUSD+123.52%
559,225.00USD—
0.00USD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Akanda Stock analysis

What does Akanda do? Akanda Corp generates revenue through its cultivation, distribution, and corporate segments. The cultivation segment focuses on producing medical cannabis and biomass, while the distribution segment sells products like those from Holigen, a Portugal-based cultivator, manufacturer, and distributor, and CanMart, a UK-based pharmaceutical importer and distributor supplying pharmacies and clinics. Holigen operates a 20,000 square foot indoor facility near Lisbon for high-THC cannabis cultivation. The company’s supply chain includes Cansativa Group, an European medical cannabis importer and distributor, and Cellen Life Sciences Leva Clinic, a UK-based digital pain clinic. Holigen’s products are distributed through Akanda’s network, targeting medical cannabis patients globally. CanMart serves UK pharmacies and clinics, leveraging its pharmaceutical licensing. Cansativa Group and Cellen Life Sciences Leva Clinic are integral to the seed-to-patient supply chain, connecting cultivation with end users. The company monetizes its portfolio by supplying ethically sourced medical cannabis products to patients worldwide through these established brands. Akanda’s revenue streams are derived from the sale of medical cannabis products via Holigen’s cultivation, CanMart’s distribution, and the supply chain involving Cansativa Group and Cellen Life Sciences Leva Clinic. The cultivation segment produces biomass for distribution, while the distribution segment handles sales to healthcare providers and clinics. The corporate segment supports these operations with strategic oversight. Akanda is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Akanda stock

Stock-Based Compensation (SBC) of Akanda is 1.25 M USD in 2023.

Stock-Based Compensation (SBC) of Akanda changed from 559,225.00 USD to 1.25 M USD, representing a 123.52% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Stock-Based Compensation (SBC) Akanda since 2006 – with annual values, charts, and detailed analysis.

Stock-based compensation is a non-cash expense representing equity awards to employees. High SBC can dilute existing shareholders and inflate reported cash flow.

Stock-Based Compensation (SBC)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Stock-Based Compensation (SBC)'s Akanda historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Akanda

All Key Metrics — Akanda